Details

Autor(en) / Beteiligte

• Hope, Thomas A
• Bergsland, Emily K
• Bozkurt, Murat Fani
• Graham, Michael
• Heaney, Anthony P
• Herrmann, Ken
• Howe, James R
• Kulke, Matthew H
• Kunz, Pamela L
• Mailman, Josh
• May, Lawrence
• Metz, David C
• Millo, Corina
• O'Dorisio, Sue
• Reidy-Lagunes, Diane L
• Soulen, Michael C
• Strosberg, Jonathan R

Titel

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Ist Teil von

• Journal of Nuclear Medicine, 2018-01, Vol.59 (1), p.66-74

Ort / Verlag

United States: Society of Nuclear Medicine

Erscheinungsjahr

2018

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Somatostatin receptor (SSTR) PET has demonstrated a significant improvement over conventional imaging (CI) in patients with neuroendocrine tumors (NETs). SSTR PET should replace 111In-pentetreotide scintigraphy (OctreoScan; Mallinckrodt) in all indications in which the latter is currently being used. These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of SSTR PET for imaging of patients with NETs. The indications were evaluated in well-differentiated NETs. Of the 12 clinical scenarios evaluated, 9 were graded as appropriate: initial staging after the histologic diagnosis of NET, evaluation of an unknown primary, evaluation of a mass suggestive of NET not amenable to endoscopic or percutaneous biopsy, staging of NET before planned surgery, monitoring of NET seen predominantly on SSTR PET, evaluation of patients with biochemical evidence and symptoms of a NET, evaluation of patients with biochemical evidence of a NET without evidence on CI or a prior histologic diagnosis, restaging at time of clinical or laboratory progression without progression on CI, and new indeterminate lesion on CI with unclear progression. Representatives from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American College of Radiology (ACR), the American Society of Clinical Oncology (ASCO), the North American Neuroendocrine Tumor Society (NANETS), the European Association of Nuclear Medicine (EANM), the Endocrine Society, the Society of Surgical Oncology, the National Comprehensive Cancer Network (NCCN), the American College of Physicians (ACP), the American Gastroenterological Association (AGA), and the World Conference on Interventional Oncology (WCIO) assembled under the auspices of an autonomous workgroup to develop the following AUC.